Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection

Lancet

Volumn 353, Issue 9161, 1999, Pages 1293-1298

  Weverling, Gerrit J ^a   Mocroft, Amanda ^b   Ledergerber, Bruno ^c   Kirk, Ole ^d   Gonzâles Lahoz, Juan ^e   Monforte, Antonella D'Arminio ^f   Proenca, Rui ^g   Phillips, Andrew N ^h   Lundgren, Jens D ⁱ   Reiss, Peter ^a  

^a Natl AIDS Therapy Evaluation Centre   (Netherlands)

^b Department of Clinical Epidemiology and Biostatistics ^*  (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^e UNIVERSITY OF ZURICH   (Switzerland)

^f HVIDOVRE HOSPITAL   (Denmark)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^h UNIVERSITY OF MILAN   (Italy)

ⁱ HOSPITAL CURRY CABRAL   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; COTRIMOXAZOLE; PROTEINASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL PRACTICE; CLINICAL TRIAL; EUROPE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; ISRAEL; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; TIME;

EID: 0009521781     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)03287-0     Document Type: Article

References (28)

1. Palella FJJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-60.
2. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS 1997; 11:F101-05.
3. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998; 352: 1725-30.
4. Torres RA, Barr M. Impact of combination therapy for HIV infection on inpatient census. N Engl J Med 1997; 336: 1531-32.
5. Hogg RS, O'Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet 1997; 349: 1294.
6. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ 1997; 315: 1194-99.
7. LopezJC, PenaJM, Miro JM, et al. Discontinuation of PCP prophylaxis is safe in HIV infected patients with immunological recovery with HAART. In: Program and abstracts of the 6th conference on retroviruses and opportunistic infections, Chicago, January 31 -February 4, 1999: page 206 (abstr LB7).
8. Furrer H, Opravil M, Bernasconi E, et al. Is it safe to stop primary PCP prophylaxis in patients treated with antiretroviral combination regimens? In: Program and abstracts of the 12th World AIDS conference, Geneva, June 28-July 3 1998. (abstr 22180).
9. Schneider MME, Borleffs JCC, Stolk RP, Japers CAJJ, Hoepelman IM. Discontinuation of Pneumonia carinii pneumonia prophylaxis in HIV-1 infected patients treated with highly active antiretroviral therapy. Lancet 1999; 353: 201-03.
10. Rodriguez-Guardado A, Maradona JA, Carton JA, Casado L, Asensi V. Pneumocystis carinii prophylaxis can be discontinued after CD4+cell recovery over 200x106/1. AIDS 1998; 12:2355-56.
11. Lundgren JD, Phillips AN, Vella S, et al. Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. J Acquir Immun Defic Syndr Hum Retrovirol 1997;16:153-60.
12. Centers for Disease Control. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992; 41: 1-19.
13. Kirk O, Mocroft A, Katzenstein T, et al. Changes in use of antiretroviral therapy in regions of Europe over time. AIDS 1998; 12: 2031-39.
14. Carr A, Tindall B, Brew BJ, et al. Low-dose trimethoprimsulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med 1992; 117: 106-11.
15. Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992; 327: 1842-48.
16. Foudraine NA, Weverling GJ, van Gool T, et al. Improvement of chronic diarrhoea in patients with advanced HIV-1 infection during potent antiretroviral therapy. AIDS 1998; 12:35-41.
17. Carr A, Marriott D, Field A, Vasak E, Cooper DA. Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet 1998; 351:256-61.
18. Elliot B, Aromin I, Gold R, Flanigan T, Mileno M. 2-5 year remission of AIDS-associated progressive multifocal leukoencephalopathy with combined antiretroviral therapy. Lancet 1997; 349: 850.
19. Hicks CB, Myers SA, Giner J. Resolution of intractable molluscum contagiosum in a human immunodeficiency virus-infected patient after institution of antiretroviral therapy with ritonavir. Clin Infect Dis 1997; 24:1023-25.
20. Li TS, Tubiana R, Katlama C, Calvez V, Ait MH, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998; 351: 1682-86.
21. Komanduri KV, Viswanathan MN, Wieder ED, et al. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med 1998; 4: 953-56.
22. 1997 USPHS/IDSA Guidelines for the prevention of opportunistic infections in persons infected with the human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1997; 46: 1-46.
23. Pakker NG, Notermans DW, de Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998;4:208-14.
24. Lundgren B, Lebech M, Lind K, Nielsen JO, Lundgren JD. Antibody response to a major human Pneumocystis carinii surface antigen in patients without evidence of immunosuppression and in patients with suspected atypical pneumonia. Eur J Clin Microbiol Infect Dis 1 993; 12: 105-09.
25. Peglow SL, Smulian AG, Linke MJ, et al. Serologie responses to Pneumocystis carinii antigens in health and disease. J Infect Dis 1990; 161:296-306.
26. Montaner JS, Lawson LM, Gervais A, et al. Aerosol pentamidine for secondary prophylaxis of AIDS-related Pneumocystis carinii pneumonia: a randomized, placebo-controlled study. Ann Intern Med 1991;114:948-53.
27. Mocroft A. Studies on the prognosis of patients with the acquired immunodeficiency syndrome. London: University of London, 1997.
28. Kaplan JE, Hanson DL, Navin TR, Jones JL. Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: reassessment of indication for chemoprophylaxis. J Infect Dis 1998; 178:1126-32.